Liver metastases: Can our understanding of their biology and prognostic Value Contribute to a strategy for Optimum therapeutic management?

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 7, 1997, Pages

  Pritchard, K I ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Liver metastases; Optimum therapeutic strategies; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; TAXANE DERIVATIVE; VINCRISTINE;

BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LIVER METASTASIS; LUNG METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE CANCER;

EID: 0031472519     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)90003-4     Document Type: Conference Paper

References (37)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 1995, 45, 12.
2. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer 1978, 41, 1170.
3. Saphir O, Parker ML. Metastasis of primary carcinoma of the breast. Arch Surg 1941, 42, 1003.
4. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 1993, 114, 637.
5. Allegra JC, Lippman ME, Thomson EB, et al. Distribution, frequency and quantitative analysis of estrogen, progesterone, androgen and glucocorticoid receptors in human breast cancer. Cancer Res 1979, 39, 1447.
6. Sherry MM, Greco FA, Johnson DH. Metastatic breast cancer confined to the skeletal system. Am J Med 1986, 81, 381.
7. Castiglione-Gertsch M, Johnsen C, Goldhirsch A. The International (Ludwig) Breast Cancer Study Group Trials I-TV: 15 years follow up. Ann Oncol 1994, 5, 717-724.
8. Nicolson GL. Differential organ tissue adhesion, invasion and growth properties of metastatic rat mammary adenocarcinoma cells. Breast Cancer Res Treat 1988, 12, 167.
9. Pauli BU, Lee CL. Organ preference of metastasis: the role of organ-specifically modulated endothelial cells. Lab Invest 1988, 58, 379-387.
10. Nicolson GL, Dulski K, Basson C, Welch DR. Preferential organ attachment and invasion in vitro by B16 melanoma cells selected for differing metastatic colonization and invasive properties. Invas Met 1985, 5, 144.
11. Nicolson GL. Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 1993, 204, 171-180.
12. Kohn EC, Francis EA, Liotta LA, Schiffmann E. Heterogeneity of the motility responses in malignant tumor cells: a biological basis for the diversity and homing of metastatic cells. Int J Cancer 1990, 46, 287.
13. Kemperman H, Wijnands Y, DeRijk D, et al. The integrin α6/β4 on TA3/Ha mammary carcinoma cells is involved in adhesion to hepatocytes. Cancer Res 1993, 53, 3611.
14. Bissell MJ, Barcellos-Hoff MH. The influence of extracellular matrix on gene expression: is structure the message (Review). J Cell Science 1987, 8, 327-343.
15. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingher D, Vlodavsky I. A heparin-binding angiogenic protein basic fibroblast growth factor is stored within basement membrane. Am J Pathol 1988, 130, 393-400.
16. Imamura T, Mitsui Y. Heparan sulfate and heparin as a potentiator or a suppressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res 1987, 172, 92-100.
17. Redini F, Moczar E, Poupon MF. Effects of glycosaminoglycans and extracellular matrix components on metastatic rat rhabdomyosarcoma tumor and myoblast cell proliferation. Clin Exp Metastasis 1990, 8, 491-502.
18. Doerr R, Zvibel I, Chiuten D, D'Olimpio J, Rejd LM. Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastases. Cancer Res 1989, 49, 384-392.
19. Perez JE, Machiavelli M, Leone BA. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. Am J Clin Oncol 1990, 13, 294.
20. Chiedozi LC. Prognostic significance of exclusive skeletal metastases in stage IV primary carcinoma of the breast. Surg Gynecol Obstet 1988, 167, 303.
21. Leone BA, Romero A, Rabinovich MG. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. Am J Clin Oncol 1988, 11, 618.
22. Scheid V, Buzdar AU, Smith TL. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986, 5, 2589.
23. Nash III CH, Jones SE, Moon TE, Davis SL, Salmon SE. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 1980, 46, 2380-2388.
24. Swenerton KD, Legha SS, Smith TL, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979, 39, 1552.
25. Smalley RV, Lefante J, Bartolucci A, et al. A comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Cancer Res Treat 1983, 3, 209.
26. George SL, Hoogstraten B. Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 1978, 60, 731.
27. Muss HB. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 1992, 21, 15-26.
28. Santen RJ, Manni A, Harvey H, et al. Endocrine treatment of breast cancer in women. Endocr Rev 1990, 11, 221.
29. Ettinger DS, Allegra J, Bertino JR, et al. Megestrol acetate vs tamoxifen in advanced breast cancer: Correlation of hormone receptors and response. Semin Oncol 1986, 13, 9-14.
30. Epstein RJ. The clinical biology of hormone-responsive breast cancer. Cancer Treat Rev 1988, 15, 33.
31. Parnes HL, Abrams JS, Tchekmedyian NS. A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1991, 18, 171.
32. Ansfield FJ, Kallas GJ, Singson JP. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast. Surg Gynecol Obstet 1982, 155, 888.
33. Ross MB, Buzdar AU, Blumenschien GR. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer 1982, 49, 413.
34. Diéras V, Fumoleau S, Kalla S, Misset JL, Azli N, Pouillart P. Docetaxel in combination with doxorubicin or vinorelbine. EurJ Cancer 1997, 33 (Suppl. 7), S20-S22.
35. Dunphy FR, Spitzer G, Fomoff JE, et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994, 73, 2157-2167.
36. Rowlings PA, Antman KS, Horowitz MM, et al. Prognostic factors in autotransplants for metastatic breast cancer. Blood 1995, 86, 618a.
37. Ayash LJ, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem cell support for advanced breast cancer. J Clin Oncol 1995, 13, 2043-2049.